|
FDXACB1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.16189999235894E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.3617999949922E-08 |
| Normal-vs-Stage2 |
5.800500E-03 |
| Normal-vs-Stage3 |
2.28990000294971E-08 |
| Normal-vs-Stage4 |
1.40830014316862E-10 |
| Stage1-vs-Stage2 |
1.628400E-01 |
| Stage1-vs-Stage3 |
1.808800E-01 |
| Stage1-vs-Stage4 |
1.700590E-03 |
| Stage2-vs-Stage3 |
4.820300E-02 |
| Stage2-vs-Stage4 |
1.541850E-03 |
| Stage3-vs-Stage4 |
6.652200E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.08290004635836E-09 |
| Normal-vs-AfricanAmerican |
9.392100E-04 |
| Normal-vs-Asian |
3.042000E-04 |
| Caucasian-vs-AfricanAmerican |
8.323000E-01 |
| Caucasian-vs-Asian |
2.867800E-01 |
| AfricanAmerican-vs-Asian |
4.611600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.0954997433148E-10 |
| Normal-vs-Female |
4.58259999946975E-08 |
| Male-vs-Female |
3.902200E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.24300000292621E-08 |
| Normal-vs-Age(41-60Yrs) |
3.27879999817426E-08 |
| Normal-vs-Age(61-80Yrs) |
5.55190000000039E-05 |
| Normal-vs-Age(81-100Yrs) |
1.602000E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.037600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.647000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.472800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.007400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.088200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.149400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.541100E-03 |
| Classical-VS-Follicular |
3.633800E-01 |
| Classical-VS-Other |
1.113550E-01 |
| Classical-VS-Normal |
1.53010000003562E-07 |
| Tall-VS-Follicular |
1.142600E-01 |
| Tall-VS-Other |
4.927000E-01 |
| Tall-VS-Normal |
9.06940000877654E-09 |
| Follicular-VS-Other |
2.234000E-01 |
| Follicular-VS-Normal |
7.85789999957487E-07 |
| Other-VS-Normal |
6.218900E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.06619999957248E-07 |
| Normal-vs-N1 |
6.27500051919583E-10 |
| N0-vs-N1 |
7.401000E-03 |
|
|
